Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology

The companies are executing on the shared vision of utilizing AI for effective knowledge management in the pharmaceutical research and development industry.

Oncotelic Therapeutics, announced a strategic partnership with Vectara, a company specializing in innovative Natural Language Understanding (NLU) technologies, to accelerate the development of novel therapies for the treatment of cancer, infectious disease, and aging.

AiThority Interview Insights: AiThority Interview with Brad Anderson, President of Product and Engineering at Qualtrics

A LLM is an artificial intelligence (AI) system that uses deep learning algorithms to generate natural language from a large corpus of text. It is trained on a large text dataset and can generate new text similar to the original dataset. Large language models are used for a variety of tasks, such as natural language processing, text generation, and machine translation. LLMs such as ChatGPT took the world by storm forever changing how we do things.

The Challenge: One of the major challenges faced by scientists and researchers is the laborious and expensive process of sifting through massive research papers and publications to find valuable statistics or data points that could aid in the innovation and creation of new or improved immunotherapies. Publicly available artificial intelligence (AI) tools lack the required depth that subject matter experts need, despite their breadth in searching a large volume of data.

The Proposed Solution: To address this challenge, scientists must create meticulously validated corpora by combining private and public research, and then applying advanced NLU algorithms interactively with a conversational AI Research Assistant.

Related Posts
1 of 38,365

The Expected Benefits: The solution is expected to speed up pharmaceutical research to gain relevant and significantly robust results by accelerating the acquisition of insights, potentially leading to groundbreaking solutions for drug discovery and formulation.

Read More about AiThority InterviewAiThority Interview with Ajay Sathyanath, Chief Technology Officer at Madison Logic

Oncotelic’s use cases demonstrate the potential for Vectara’s innovative LLM-powered search in areas like life sciences and healthcare, where the demands for scientific accuracy limit the usefulness of most conversational AI tools. Vectara’s “Grounded Generation” ensures that responses to the questions posed are constrained only to the relevant and specific source data set.

“We are proud to work with a growing number of research & analysis firms that, through AI, are rediscovering their most significant competitive advantage – extracting value from their treasure-trove of research data through LLM-powered search,” said Amr Awadallah, Vectara’s CEO and Founder. “I am especially proud of our partnership with Oncotelic. It is rewarding to play a role in bringing much needed treatments to patients.”

“We are excited to combine Vectara’s advanced NLU technology with our internal AI discovery and development programs to revolutionize drug discovery and development. This partnership represents a significant step forward for both companies, and we are eagerly anticipating the outcomes from this venture,” said Saran Saund, Oncotelic’s Chief Business Officer.

 Latest AiThority Interview Insights : AiThority Interview with at Brian Sathianathan, Co-Founder and CTO at

 [To share your insights with us, please write to] 

Comments are closed.